Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts

• Main Authors: Annett Klinder (Author), Janine Waletzko-Hellwig (Author), Marie-Luise Sellin (Author), Anika Seyfarth-Sehlke (Author), Markus Wolfien (Author), Franziska Prehn (Author), Rainer Bader (Author), Anika Jonitz-Heincke (Author)
• Format: Book
• Published: MDPI AG, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Interleukin (IL-) 6 is a key factor in the inflammatory processes of rheumatoid arthritis. Several biologic agents target the IL-6 signaling pathway, including sarilumab, a monoclonal antibody that blocks the IL-6 receptor and inhibits IL-6-mediated cis- and trans-signaling. A careful analysis of th...